Haemonetics Profit Margin vs. Return On Asset

HAE Stock  USD 90.75  1.03  1.12%   
Based on Haemonetics' profitability indicators, Haemonetics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess Haemonetics' ability to earn profits and add value for shareholders.

Haemonetics Net Profit Margin

0.0504

The current year's Price To Sales Ratio is expected to grow to 4.27. The current year's Days Sales Outstanding is expected to grow to 61.06. At present, Haemonetics' Income Before Tax is projected to increase significantly based on the last few years of reporting. The current year's Net Income is expected to grow to about 123.4 M, whereas Total Other Income Expense Net is forecasted to decline to (13.7 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.460.5168
Fairly Down
Slightly volatile
For Haemonetics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Haemonetics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Haemonetics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Haemonetics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Haemonetics over time as well as its relative position and ranking within its peers.
  

Haemonetics' Revenue Breakdown by Earning Segment

Check out Risk vs Return Analysis.
For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.375
Earnings Share
2.39
Revenue Per Share
26.77
Quarterly Revenue Growth
0.086
Return On Assets
0.0588
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Haemonetics Return On Asset vs. Profit Margin Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Haemonetics's current stock value. Our valuation model uses many indicators to compare Haemonetics value to that of its competitors to determine the firm's financial worth.
Haemonetics is rated below average in profit margin category among its peers. It is rated # 4 in return on asset category among its peers reporting about  0.65  of Return On Asset per Profit Margin. The ratio of Profit Margin to Return On Asset for Haemonetics is roughly  1.55 . At present, Haemonetics' Net Profit Margin is projected to increase slightly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Haemonetics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Haemonetics Return On Asset vs. Profit Margin

Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

Haemonetics

Profit Margin

 = 

Net Income

Revenue

X

100

 = 
0.09 %
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Haemonetics

Return On Asset

 = 

Net Income

Total Assets

 = 
0.0588
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Haemonetics Return On Asset Comparison

Haemonetics is currently under evaluation in return on asset category among its peers.

Haemonetics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Haemonetics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Haemonetics will eventually generate negative long term returns. The profitability progress is the general direction of Haemonetics' change in net profit over the period of time. It can combine multiple indicators of Haemonetics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-35.6 M-37.4 M
Operating Income164.9 M173.1 M
Income Before Tax151.9 M159.5 M
Total Other Income Expense Net-13 M-13.7 M
Net Income117.6 M123.4 M
Income Tax Expense34.3 M17.5 M
Net Income Applicable To Common Shares132.7 M139.3 M
Net Income From Continuing Ops117.6 M123.4 M
Non Operating Income Net Other-13.2 M-13.8 M
Interest Income16.8 M13.3 M
Net Interest Income-13 M-13.7 M
Change To Netincome41.6 M40.4 M
Net Income Per Share 2.32  0.86 
Income Quality 1.55  4.84 
Net Income Per E B T 0.77  0.76 

Haemonetics Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Haemonetics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Haemonetics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Haemonetics' important profitability drivers and their relationship over time.

Use Haemonetics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Haemonetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Haemonetics will appreciate offsetting losses from the drop in the long position's value.

Haemonetics Pair Trading

Haemonetics Pair Trading Analysis

The ability to find closely correlated positions to Haemonetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Haemonetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Haemonetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Haemonetics to buy it.
The correlation of Haemonetics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Haemonetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Haemonetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Haemonetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Haemonetics position

In addition to having Haemonetics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Asset Management Thematic Idea Now

Asset Management
Asset Management Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Asset Management theme has 7 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Asset Management Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:
Check out Risk vs Return Analysis.
For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
To fully project Haemonetics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Haemonetics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Haemonetics' income statement, its balance sheet, and the statement of cash flows.
Potential Haemonetics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Haemonetics investors may work on each financial statement separately, they are all related. The changes in Haemonetics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Haemonetics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.